Latest Commercialisation News

Osteopore Limited has secured non-exclusive distribution rights for an injectable regenerative bone filler across Southeast Asia, marking a strategic expansion of its orthopaedic product portfolio and opening new revenue channels.

Locksley Resources has produced 99.5% pure antimony trioxide from its Desert Antimony Mine feedstock, marking a key step toward restoring a fully domestic U.S. supply chain for this critical mineral.

Temas Resources has reported significant assay results from its 2025 drilling at the La Blache Project, revealing thick zones rich in gallium, scandium, and chromium alongside titanium, vanadium, and iron. The company’s proprietary RCL technology promises to unlock additional value from this multi-element mineralisation.

St George Mining has formed a strategic alliance with Brazilian nanotechnology firm Nanum Nanotecnologia to enhance the processing and commercialisation of rare earth elements from its Araxá Project, aiming to upgrade high-value magnet and heavy rare earth concentrations.

Neometals has secured a 30-day extension to its exclusivity period with BML Ventures for the Ironclad Deposit development, allowing both parties to finalise due diligence and internal studies ahead of a joint venture agreement.

Condor Energy has updated its corporate presentation revealing significant progress in Peru’s Tumbes Basin, highlighting a 1 trillion cubic feet gas discovery and a multi-billion barrel oil exploration portfolio. The company is moving towards converting its evaluation agreement into a full exploration licence while advancing commercial discussions for gas offtake.

Dimerix Limited has completed dosing of the last adult patient in its ACTION3 Phase 3 trial for DMX-200, exceeding its recruitment target and setting the stage for key regulatory milestones.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Galilee Energy has confirmed the Zydeco-1 well is drill-ready following enhanced 3D seismic analysis, aiming to tap up to 8 billion cubic feet of gas and 0.5 million barrels of condensate in Louisiana with spudding planned for the second quarter of 2026.